Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Objective To examine the metabolic effects and body composition changes after topiramate treatment of obese type 2 diabetic patients (DM2) for 11 months. Design and subjects Thirty-eight DM2 on diet or sulfonylurea treatment participated in this randomized double-blind placebo-controlled trial. Thirteen placebo-treated and nine topiramate-treated patients completed the trial. Patients were randomized to treatment with topiramate 96 mg b.i.d. or placebo (6-week run-in phase, 2-months titration phase, 9-months maintenance phase). Measurements Insulin sensitivity was measured with euglycaemic hyperinsulinemic clamps. Weight, HbA1c, fasting glucose, blood lipids and safety variables were measured at regular intervals. Body composition was determined with computerized tomography. Meal tests were performed to evaluate postprandial glucose and insulin levels. Three-day diet recalls were carried out to evaluate energy ingestion. Results The mean age was 58.6+/-7.1 years, body weight 98.1+/-16.1 kg, BMI 33.0+/-4.5 kg/m(2), and glycosylated hemoglobin (HbA1c) 7.3+/-0.9%. In topiramate-treated patients, there were significant reductions in HbA1c (1.1+/-0.9%), fasting plasma glucose, body weight (-6.6+/-3.3%), as well as body fat, lean body mass, postprandial glucose and free fatty acid levels but there were no significant changes in insulin sensitivity. The daily average energy intake decreased more in the topiramate group than in the placebo group. Paresthesia and central nervous syste…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Topiramate negatively affects BMD383 but might not affect lean mass384,385.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [384]
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065 · cited 3×
“Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial B Eliasson1, S Gudbjörnsdottir1, J Cederholm2, Y Liang3, F Vercruysse4 and U Smith1 1Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Göteborg…”
BackgroundInfluentialPetersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Kvist, H., Chowdhury, B., Grangård, U., Tylén, U., & Sjöström, L. (1988) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/48.6.1351 · Cited by 794
Determination of total adipose tissue and body fat in women by computed tomography, 40K, and tritium
Sjostrom, L., Kvist, H., Cederblad, A., & Tylen, U. (1986) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1986.250.6.e736 · Cited by 368
Bray, G. A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., & Perry, B. H. (2003) · Obesity Research · doi:10.1038/oby.2003.102 · Cited by 344
Sopasakis, V. R., Sandqvist, M., Gustafson, B., Hammarstedt, A., Schmelz, M., Yang, X., Jansson, P., & Smith, U. (2004) · Obesity Research · doi:10.1038/oby.2004.51 · Cited by 243
Self-citationTopiramate vs placebo in painful diabetic neuropathy: Analgesic and metabolic effects
Raskin, P., Donofrio, P. D., Rosenthal, N. R., Hewitt, D. J., Jordan, D. M., Xiang, J., & Vinik, A. I. (2004) · Neurology · doi:10.1212/01.wnl.0000137341.89781.14 · Cited by 239
for the OBES-002 Study Group, Wilding, J., Gaal, L. V., Rissanen, A., Vercruysse, F., & Fitchet, M. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802783 · Cited by 224
Self-citationPredictors of Weight Loss in Adults with Topiramate‐Treated Epilepsy
Ben‐Menachem, E., Axelsen, M., Johanson, E. H., Stagge, A., & Smith, U. (2003) · Obesity Research · doi:10.1038/oby.2003.78 · Cited by 202
Self-citation
Cited by
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Efficacy and safety of topiramate on weight loss: a meta‐analysis of randomized controlled trials
Kramer, C. K., Leitão, C. B., Pinto, L. C., Canani, L. H., Azevedo, M. J., & Gross, J. L. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00846.x · Cited by 323
“Eliasson B, 2007 (39) BMI 27 kg m-2 and type 2 diabetes on diet”
BackgroundThe Evidence for Medical Nutrition Therapy for Type 1 and Type 2 Diabetes in Adults
Franz, M. J., Powers, M. A., Leontos, C., Holzmeister, L. A., Kulkarni, K., Monk, A., Wedel, N., & Gradwell, E. (2010) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2010.09.014 · Cited by 306
Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes
Scheen, A. J., & Van Gaal, L. F. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70004-x · Cited by 190
Central control of thermogenesis
Clapham, J. C. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.014 · Cited by 140
“…noted as a side effect in clinical trials for topiramate (Guerrini and Parmeggiani, 2006) and subsequent studies with body weight as an endpoint indicated that topiramate may be useful in the treatment of obesity (Astrup et al., 2004; Bray et al., 2003; Eliasson et al., 2007; Kramer et al., 2011).”
Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs
Nathan, P. J., O’Neill, B. V., Napolitano, A., & Bullmore, E. T. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00172.x · Cited by 113
“A number of more recent studies conducted in obese patients [144], obese type 2 diabetic patients [145–147] and binge eating disorder associated with obesity [148] have similarly reported higher incidence of cognitive impairment, depression/mood problems and anxiety/nervousness following topiramate treatment.”
ResultBlevins, J. E., Thompson, B. W., Anekonda, V. T., Ho, J. M., Graham, J. L., Roberts, Z. S., Hwang, B. H., Ogimoto, K., Wolden‐Hanson, T., Nelson, J. T., et al. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00220.2015 · Cited by 113
Orlistat: current status in clinical therapeutics
McClendon, K. S., Riche, D. M., & Uwaifo, G. I. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903321485 · Cited by 93
“Of all these, only topiramate has shown the potential for producing weight loss that may equal or exceed that documented with the FDA approved options though with a significant degree for mainly CNS side effects [112-115].”
BackgroundPharmacologic Therapies for Obesity
Kaplan, L. M. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.01.001 · Cited by 76
The Most Undertreated Chronic Disease: Addressing Obesity in Primary Care Settings
Tucker, S., Bramante, C., Conroy, M., Fitch, A., Gilden, A., Wittleder, S., & Jay, M. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00444-y · Cited by 73
Bays, H. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.125 · Cited by 66
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
Gadde, K., & Shin (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s43403 · Cited by 54
The role of carbonic anhydrase in the pathogenesis of vascular calcification in humans
Adeva‐Andany, M. M., Fernández‐Fernández, C., Sánchez-Bello, R., Donapetry, C., & Martínez‐Rodríguez, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.05.012 · Cited by 52
Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice
Gadde, K. M., & Raj, Y. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0859-2 · Cited by 51
Topiramate, nutrition and weight change: a prospective study
Klein, K. M., Theisen, F., Knake, S., Oertel, W. H., Hebebrand, J., Rosenow, F., & Hamer, H. M. (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.136929 · Cited by 42
Li, Q. S., Lenhard, J. M., Zhan, Y., Konvicka, K., Athanasiou, M. C., Strauss, R. S., & Francke, S. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000185 · Cited by 38
Hahn, M., Remington, G. J., Bois, D., & Cohn, T. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181fab67d · Cited by 41
Pharmaceutical “Gold” from Neurostabilizing Agents: Topiramate and Successor Molecules
Maryanoff, B. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900141j · Cited by 33
Parker, M. H., Smith‐Swintosky, V. L., McComsey, D. F., Huang, Y., Brenneman, D. E., Klein, B. D., Malatyńska, E., White, H. S., Milewski, M. E., Herb, M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801432r · Cited by 35
Psychopharmacology of Eating Disorders in Children and Adolescents
Golden, N. H., & Attia, E. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2010.11.001 · Cited by 32
Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice
Gadde, K. M. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.890590 · Cited by 29
“There is evidence that it may have an insulin-sensitizing effect, and studies in patients with type 2 diabetes have consistently demonstrated improved glycemic control [91-94].”
BackgroundDrug‐Induced Hyperphagia: What Can We Learn From Psychiatric Medications?
Jensen, G. L. (2008) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607108321708 · Cited by 26
“Topiramate has been subject to testing as a weight loss medication but has had a limiting side effect profile with paresthesias and central nervous system effects.(47) Weight gain with lithium is observed in up to 65% of patients; 20% of patients gain 10 kg or more with long-term therapy.”
Topiramate in Schizophrenia: A Review of Effects on Psychopathology and Metabolic Parameters
Hahn, M., Cohn, T. A., Teo, C., & Remington, G. J. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.haco.01062013 · Cited by 28
Topiramate (Topamax): Evolving Role in Weight Reduction Management: A Narrative Review
Wajid, I., Vega, A., Thornhill, K., Jenkins, J. S., Merriman, C., Chandler, D., Shekoohi, S., Cornett, E. M., & Kaye, A. D. (2023) · Life · doi:10.3390/life13091845 · Cited by 35
“Eliasson et al. noted that in obese patients diagnosed with Type 2 diabetes, treatment of topiramate for 11 months as an adjunctive showed significantly reduced body weight and improved glycemia con-trol [16].”
The effect of topiramate on weight loss in patients with type 2 diabetes.
Moradi, S., Kerman, S. R. J., & Mollabashi, M. (2013) · PubMed Central · Cited by 23
Effects of topiramate on diabetes mellitus induced by streptozotocin in rats
Shafik, A. N. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.03.042 · Cited by 19
Phentermine, Sibutramine and Affective Disorders
An, H., Sohn, H., & Chung, S. (2013) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2013.11.1.7 · Cited by 17
Adolescents with Type 2 Diabetes: Overcoming Barriers to Effective Weight Management
Salama, M., Biggs, B. K., Creo, A. L., Prissel, R., Nofal, A. A., & Kumar, S. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s365829 · Cited by 16
“3 kg and decrease in body fat in lean body mass.(134) There was decrease in daily average energy intake in the topiramate group.”
BackgroundGenç, B. O., Doğan, E. A., Doğan, U., & Genç, E. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.01.045 · Cited by 16
Current Perspectives for Treating Adolescents with Obesity and Type 2 Diabetes: A Review
Niechciał, E., Wais, P., Bajtek, J., & Kędzia, A. W. (2024) · Nutrients · doi:10.3390/nu16234084 · Cited by 26
Paravattil, B., Wilby, K. J., & Turgeon, R. D. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.02.002 · Cited by 13
Effects of topiramate use on body composition and resting metabolic rate in migraine patients
Yaman, M., Ucok, K., Demirbas, H., Genc, A., Oruc, S., Karabacak, H., & Koyuncu, G. (2013) · Neurological Sciences · doi:10.1007/s10072-012-0977-1 · Cited by 12
“Many studies have been performed also in obesity treatment because of this preferable side effect of TPM and weight-reducing effect has been shown [21, 22].”
BackgroundInteractions with Drugs and Dietary Supplements Used For Weight Loss
Jordan, M. (2013) · InTech eBooks · doi:10.5772/51145 · Cited by 10
“Weight loss has been a commonly reported adverse effect of topiramate; therefore, the drug has recently come into focus as a potential anorectic agent [38-42].”
BackgroundJahangiri, L., Kesmati, M., & Najafzadeh, H. (2014) · PubMed Central · Cited by 12
Bomberg, E. M., Clark, J., Rudser, K. D., Gross, A. C., Kelly, A. S., & Fox, C. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1369270 · Cited by 8
Manitpisitkul, P., Curtin, C. R., Shalayda, K., Wang, S., Ford, L., & Heald, D. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0143-4 · Cited by 8
“topiramate has shown both insulin secretagogue [8] and sensitizing action [9] in rats and results in weight loss in obese patients with T2DM [7].”
BackgroundRodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Clinical Practice Guideline for the Management of Overweight and Obesity in Adults in Saudi Arabia
Alshaikh, A., Al-Jedai, A. H., Alfadda, A. A., Al-Robayan, A. A., Bawahab, A., Abo’ouf, S., Sultan, A., Alhozali, A. M., Bawazeer, M. A., Sheshah, E., et al. (2022) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2022.1312045 · Cited by 9
Sleddering, M. A., Snel, M., Streefland, T. C. M., Pijl, H., & Jazet, I. M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0500 · Cited by 7
Ma, L., Lu, Q., Lim, S. K., Han, G., Boros, L. G., Desai, M., & Yee, J. K. (2025) · Nutrients · doi:10.3390/nu17030564 · Cited by 7
“Human studies have reported positively on the weight-loss-promoting and insulin-sensitizing properties of topiramate [13–15], in addition to improvements in circulating lipid levels.”
Topiramate administration decreases body weight and preserves lean body mass in hemicranic women
Sabato, F. D., Fiaschetti, P., Albanese, C. V., Passariello, R., Fanelli, F. R., & Laviano, A. (2009) · e-SPEN the European e-Journal of Clinical Nutrition and Metabolism · doi:10.1016/j.eclnm.2009.03.001 · Cited by 6
Antiepileptic Drugs in Obesity, Psychotropic-Associated Weight Gain, and Eating Disorders
McElroy, S. L., Guerdjikova, A. I., Keck, P. E., Pope, H. G., & Hudson, J. I. (2008) · Medical psychiatry · doi:10.3109/9780849382666.016 · Cited by 6
Bollinger, B., Cotter, R. J., Deng, Y., Ilagan‐Ying, Y. C., & Gupta, V. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08724-y · Cited by 3
Assessment of the Obese Patient
Bessesen, D. H. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1203-2_12 · Cited by 3
Lee, M. J., Yom, Y. S., Lim, H. W., Kim, S. T., Lee, Y. M., Cho, Y. Z., Lee, K. W., Kim, B.-J., Park, K. Y., & Lim, D. M. (2009) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2009.24.4.277 · Cited by 1
“또한 비만인 제2형 당뇨병환자의 치 료에 topiramate를 사용해 본 몇몇 연구에서는[13,14] 체중 감소와 체지방 감소에 의한 효과로 설명하였으나 이외에도 간이나 췌장에서의 인슐린에 대한 작용이 있을 가능성도 배 제할 수 없어 더 많은 연구가 필요하다 하였다.”
Assessment of the Obese Patient
Bessesen, D. H. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2311-3_12 · Cited by 1
Gewichtsveränderungen unter Antiepileptikagabe
Rosenow, F., Hamer, H. M., & Klein, K. M. (2009) · Clinical Epileptology · doi:10.1007/s10309-009-0042-0
An Approach to Obesity as a Cardiometabolic Disease: Potential Implications for Clinical Practice
Saban-Ruiz, J., Fabregate-Fuente, M., Fabregate-Fuente, R., Alonso-Pacho, A., González-Quevedo, C. D. L. P., Blasco, S. T., Guerri, A., Andres, A., & Barrio, D. (2014) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608059140114020003 · Cited by 3
“Around one third of obese subjects will develop T2DM, but if we take into account pre-diabetes, this figure raises over 50%, which is the percentage of patients with hyperglycemia.”
BackgroundInfluentialAdrenal sushing syndrome shortly after Adrenal insufficiency
Milanesi, A., Dhall, D., Yu, R., Pitoia, F., Abelleira, E., Nièpomniszcze, H., Chen, Y., Barry, T., Giasson, J., Azizi, G., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.4.656
Clinical Features of Refractory Status Epilepticus in Various Conditions
Wang, X., Zhang, Y., & Leung, H. (2017) · Springer eBooks · doi:10.1007/978-981-10-5125-8_4
Antiseizure Medications and Weight Change
Asadi‐Pooya, A. A., & Sperling, M. R. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780197541210.003.0029
The Effects of Topiramate on Methotrexate- Induced Pancreatic Injury
Mercantepe, F., & Tümkaya, L. (2023) · Selçuk Tıp Dergisi · doi:10.30733/std.2023.01643
Yamamoto, H. H., Napoli, T. F., & Salles, J. E. N. (2024) · medRxiv · doi:10.1101/2024.05.25.24307923
“However, more studies are needed, questioning whether this effect would not be a direct consequence of weight loss by the medication [35,41,42] .”
BackgroundMethodInfluentialBartoszek, A., Paszkowska, E., Kozub-Pędrak, A., Sumara, A., & Fornal, E. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1549993 · Cited by 1
Shi, C., Li, S., Liang, Y., Ma, D., Hu, Z., Wang, Y., Wang, Z., Qi, S., Hao, X., Li, M., et al. (2026) · Headache The Journal of Head and Face Pain · doi:10.1111/head.70079 · Cited by 1
Self-citationGliclazide-Topiramate Interaction Studies in Rats and Rabbits
Gadiko, C., & Kilari, E. K. (2026) · Asian Journal of Pharmaceutical Research and Health Care · doi:10.4103/ajprhc.ajprhc_65_26
Metadata
- Authors
- Eliasson, B., Gudbjörnsdottir, S., Cederholm, J., Liang, Y., Vercruysse, F., & Smith, U.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Uppsala University Hospital (SE)
- Janssen Research & Development (United States) (US)
- Corresponding author
- Eliasson, B
- Venue
- International Journal of Obesity
- Published
- 2007-02-13
- Volume
- 31
- Issue
- 7
- Pages
- 1140-1147
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W2052347592
- Cited by
- 57
- References
- 22
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 2 · 2021: 1 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 6 · 2013: 6 · 2012: 3
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- topiramate, type 2 diabetes, obesity, weight loss, body composition, insulin sensitivity, glycemic control, HbA1c, fat mass, energy intake, postprandial blood glucose, insulin secretion, adverse effects
- MeSH terms
- Topiramate, Adult, Aged, Body Composition, Cells, Cultured, Diabetes Mellitus, Type 2, Dietary Fats, Double-Blind Method, Drug Therapy, Combination, Female, Fructose, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Middle Aged, Obesity, Placebos, Sulfonylurea Compounds, Weight Loss, Cytokines, Adipocytes, Anti-Obesity Agents, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.